The antitumor effect of IL-17 is synergistic with that of IFN-γ, which stimulates tumor cells to release the chemokines CXCL9 and CXCL10 to recruit NKs and CTLs into tumor sites [140, 142] (Figure 3). The gene discussed is CXCL10; the disease is neoplasm.